General Administration of Market Supervision: Strengthening anti-monopoly law enforcement in the field of APIs

Home > Finance

General Administration of Market Supervision: Strengthening anti-monopoly law enforcement in the field of APIs

2018-12-07 20:25:42 40 ℃

Phoenix Network Financial News Beijing time on Thursday (December 6), according to the General Administration of Market Supervision, the three glacial acetic acid raw material manufacturers to implement monopoly behavior was punished by 12.83 million yuan. The General Administration of Market Supervision said that it will continue to strengthen anti-monopoly law enforcement in the field of APIs and severely crack down on various monopolistic behaviors such as monopoly price increases.

The following is the full text:

Three glacial acetic acid APIs The monopolistic behavior of production enterprises was punished by 12.83 million yuan in accordance with the law.

In July this year, the General Administration of Market Supervision received a report, reflecting the joint price increase of some glacial acetic acid raw material drug operators, which harmed downstream pharmaceutical manufacturers and patients. . After receiving the report, the General Administration of Market Supervision launched an anti-monopoly investigation. The survey found that from October 2017 to February 2018, Chengdu Huasheng Pharmaceutical Excipients Manufacturing Co., Ltd., Sichuan Jinshan Pharmaceutical Co., Ltd. and Guangdong Taishan Xinning Pharmaceutical Co., Ltd. were involved in the production and sale of glacial acetic acid APIs. , exchange market prices many times, exchange production and sales information, discuss the issue of joint price increases. After many deliberations, the three companies involved in the case finally reached a monopoly agreement to jointly increase the sales price of glacial acetic acid bulk drug. From March 1st, the sales price of glacial acetic acid raw material drug increased from 7-9 yuan/kg to 28-33 yuan. /kg, and sell it at this price.

The above-mentioned acts of the enterprises involved in the case violated the relevant provisions of the "Anti-Monopoly Law of the People's Republic of China". The General Administration of Market Supervision recently imposed administrative penalties according to law, ordering the three enterprises to stop the illegal acts; confiscation of illegal income of RMB 6,582,200; The enterprise was fined 4% of the previous year's sales, accounting for 6,516,600 yuan. A total of 12.833 million yuan was fined for three companies involved in the case.

As a raw material medicine, glacial acetic acid is mainly used for the production of hemodialysis concentrates for the treatment of diseases such as advanced kidney failure and uremia. The monopolistic behavior of the three companies is serious and the damage is deep. First, it severely excluded and restricted market competition. As the only three glacial acetic acid producers on the market, after the monopoly agreement was reached and implemented, the price of glacial acetic acid bulk drug was unified, which seriously undermined the market competition order. The second is to increase the burden on downstream pharmaceutical companies. Glacial acetic acid is the main raw material for hemodialysis concentrate. The sharp increase in price directly increases the downstream production cost and increases the cost burden of downstream pharmaceutical companies. The third is to harm the normal treatment of dialysis patients. The price of glacial acetic acid bulk drug is soaring, which causes downstream pharmaceutical companies to reduce production and stop production of hemodialysis concentrate, which will harm the normal treatment of hemodialysis patients. After receiving the anti-monopoly investigation, the three companies have restored the sales price of glacial acetic acid bulk drug to a competitive state and ensure the normal supply of the market.

At present, monopolistic behaviors in the field of APIs have occurred from time to time, jeopardizing the legitimate rights and interests of patients and pharmaceutical manufacturers, and undermining the market order of fair competition. The General Administration of Market Supervision will continue to strengthen anti-monopoly law enforcement in the field of APIs, severely crack down on various monopolistic behaviors such as monopoly price increases, protect the legitimate rights and interests of patients and related operators, and create a fair competitive market environment.